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Abstract
The discovery of new anti-infective compounds is stagnating and multi-resistant bacteria continue to emerge, threatening
to end the ‘‘antibiotic era’’. Antimicrobial peptides (AMPs) and lipo-peptides such as daptomycin offer themselves as a new
potential class of antibiotics; however, further optimization is needed if AMPs are to find broad use as antibiotics. In the
present work, eight analogues of mastoparan-X (MPX) were investigated, having side chain modifications in position 1, 8
and 14 to modulate peptide hydrophobicity. The self-association properties of the peptides were characterized, and the
peptide-membrane interactions in model membranes were compared with the bactericidal and haemolytic properties.
Alanine substitution at position 1 and 14 resulted in higher target selectivity (red blood cells versus bacteria), but also
decreased bactericidal potency. For these analogues, the gain in target selectivity correlated to biophysical parameters
showing an increased effective charge and reduction in the partitioning coefficient for membrane insertion. Introduction of
an unnatural amino acid, with an octyl side chain by amino acid substitution, at positions 1, 8 and 14 resulted in increased
bactericidal potency at the expense of radically reduced membrane target selectivity. Overall, optimized membrane
selectivity or bactericidal potency was achieved by changes in side chain hydrophobicity of MPX. However, enhanced
potency was achieved at the expense of selectivity and vice versa in all cases.
Citation: Henriksen JR, Etzerodt T, Gjetting T, Andresen TL (2014) Side Chain Hydrophobicity Modulates Therapeutic Activity and Membrane Selectivity of
Antimicrobial Peptide Mastoparan-X. PLoS ONE 9(3): e91007. doi:10.1371/journal.pone.0091007
Editor: Mark J. van Raaij, Centro Nacional de Biotecnologia - CSIC, Spain
Received October 1, 2013; Accepted February 7, 2014; Published March 12, 2014
Copyright:  2014 Henriksen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Danish Research Council (FSS), the Strategic Research Council, the Danish Research Council for Technology and Innovation, and the Technical
University of Denmark have funded the current project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jonas.henriksen@kemi.dtu.dk
. These authors contributed equally to this work.
Introduction
Antibiotics are one of the most important inventions in
biomedical research, yearly saving the lives of millions of people.
With the discovery of penicillin by Alexander Fleming in 1928, the
‘‘antibiotic era’’ and research in antibiotics was initiated, which led
to the invention of drugs like methicillin, vancomycin, linezolid,
and the lipo-peptide daptomycin [1]. However, the wide use of
anti-infective drugs in hospitals and industrial farming has
spawned the emergence of multi-drug resistant bacterial strains
[2], and the demand for new and more potent drugs is imperative
[1].
Antimicrobial peptides (AMPs) offer themselves as potential
drugs for treating bacterial, fungal, and viral infections, and thus as
a new class of antibiotics. In higher eukaryotes such as plants and
vertebrates, antimicrobial peptides are a natural part of the innate
immune system, and serve as the first line of defence against
infections [3]. In humans, these peptides are primarily located on
skin and on mucosal surfaces, where they protect e.g. the oral
tract, lungs, and intestines against bacterial and fungal infections.
Important human AMP classes are the defensins, cathelicidins,
and histatins [4]. These small molecule drugs have been optimized
though evolution to combat invading microorganisms, and several
have been shown to exhibit activity towards various bacteria,
viruses, fungi, and parasites [5].
AMPs are cationic amphipathic molecules with a typical size of
10–40 amino acids, which carry a net positive charge (typically 1–
10 charged residues). The sequence of the peptide is comprised of
hydrophilic and hydrophobic amino acid residues, rendering the
peptide soluble in both aqueous and lipid phases. In water, the
peptide is largely unstructured. Upon insertion into lipid
membranes, the peptide adopts a secondary structure, and
displaces the hydrophobic and hydrophilic residues of the peptide
onto two different faces, which facilitate the insertion into the
membrane [6]. Typical secondary structures attained upon
membrane insertion are the beta-sheet and alpha-helical peptide
conformations. Once inserted into the membrane, the mode of
action differs between peptides; some translocate across the
membrane [7,8], some associate into clusters [9] while others
form pores on the membrane [10,11]. Both peptide clusters and
pores are heterogeneous structures that permeabilize the mem-
brane. The advantages of AMPs over conventional antibiotics are
numerous; they exhibit broad-spectrum activity, they operate via
non-receptor mediated mechanisms, and most importantly, they
rarely induce resistance [12]. However, AMPs have not yet
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reached their potential as novel antibiotics, and further explora-
tion of these compounds is needed.
From a biophysical point of view, the interaction of AMPs with
various types of lipid membranes has been well characterized, and
it is argued in the literature that the peptides’ ability to select
between mammalian and bacterial membranes is governed by
electrostatic interactions between the AMP and the target
membrane [13,14,15]. Moreover, formation of secondary struc-
ture has been shown to be a driver for peptide insertion into
membranes [16]. Based on this knowledge, several strategies for
optimization of AMPs potency have been investigated including: (i)
Increase of peptide charge [17], (ii) modulation of hydrophobicity
and hydrophobic moment [18,19] and (iii) stabilization/destabi-
lization of the peptide secondary structure [20,21]. However,
balancing peptide hydrophobicity and hydrophilicity is non-trivial,
which renders the optimization process far from straight forward.
The present work, focus on enhancing the understanding of
how changes in peptide hydrophobicity, via acylation or
alkylation, impacts selectivity and potency of the peptide. Within
this line of optimization, acylation of potent midsized AMPs (15–
30 AA) [22,23,24] and ultra short tetra and penta peptides [25,26]
have been investigated among others. In most studies, a N-
terminal conjugation strategy is utilized because of simplicity. This
approach has resulted in peptides with higher and broader activity
spectrum; however, the activity has been achieved at the expense
of membrane/target selectivity leading to more haemolytic
analogues [26,27]. The majority of these studies emphasize
bactericidal potency of the peptide as their key optimization
parameter and pay less attention to haemolytic properties, mode of
membrane action, aggregation and folding etc. As a consequence,
the selected peptide analogues are often more haemolytic than the
native peptides, which hampers their use. Therefore, many studies
of C4–C18 acylated peptides point to the conclusion that C12–
C14 constitutes the optimal acyl chain length range [22,26].
However, peptide selectivity is tightly connected to the balance of
hydrophilic and hydrophobic residues. Therefore, the proper
acyl/akyl chain length to use (if any) depends on the hydropho-
bicity of the native peptide as well as the position of alkylation/
acylation on the peptide backbone.
In a recent work, we discovered that membrane selectivity and
affinity of mastoparan X (MPX) were enhanced by short-chain
acylation. In addition, selectivity was abolished by medium-chain
acylation, possibly rendering the investigated octanoic acid
analogue inefficient in targeting bacteria over mammalian cells
[14]. Moreover, we hypothesized that the observed changes in
membrane selectivity and affinity were linked to the small
proximity of the acylation point at the N-terminal and neigh-
bouring charges. In the present study, we expand on these
observations via an extended set of MPX analogues containing six
new analogues. The full set of peptides is characterized using
biophysical methods and is screened for haemolytic and bacteri-
cidal activity. Native MPX (H-INWKGIAAMAKKLL-NH2) is a
14 amino acid peptide with a net positive charge of +4. MPX
belongs to the mastoparan family of antimicrobial peptides, and is
found in high concentration in wasp venom [27]. MPX displays
considerable antimicrobial activity against Gram-positive bacteria;
however, MPX also shows substantial haemolytic activity. The
current set of peptides contains eight synthesized MPX analogues
as shown in Fig. 1. Ala1 and Ala14 have an alanine substitution at
position 1 or 14, Leu8 has a leucine substitution at position 8,
Adec1, Adec8 and Adec14 have a 2-amino-decanoic acid
substitution at position 1, 8 or 14, respectively. PAMPX and
OAMPX are the Na-terminal propanoic and octanoic acid acyl
analogues of MPX, respectively, which were investigated previ-
ously [14]. The new analogues (Ala1, Ala14, Leu8, Adec1, Adec8
and Adec14) are designed to have varying hydrophobicity, at
position 1, 8 and 14 of the MPX sequence, while keeping the
peptide charge constant; a condition that is not met by the N-
terminal acylated analogues PAMPX and OAMPX. Thus, the
current set of peptides contain analogues of constant nominal
charge, with either an Ala, Leu (or Ile) or 2-amino-decanoic acid
substitutions at each position (1, 8 or 14), which provides a side-
chain size-range from C1 to C4 to C8.
In order to reveal effects related to changes in side-chain
hydrophobicity and/or peptide backbone alkylation position, these
peptide analogues were screened for their mode of membrane
interaction, tendency to aggregate, membrane partitioning and
haemolytic and bactericidal properties.
Materials and Methods
Materials
All Fmoc (9H-fluoren-9-yl-methyloxycarbonyl) L-amino acids
and HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-tria-
zolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, N-[(Dimethy-
lamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide) were pur-
chased from GLS China (GL Biochem, Shanghai, China). Fmoc-
2-amino-decanoic acid was obtained from Watanabe Chemical
Industries, Ltd (Hiroshima, Japan). Lys and Trp were side-chain-
protected as tert-butoxycarbonyl, Asn was sidechain protected
with trityl. Tentagel resin was purchased from NovaBiochem
(Merck, Darmstadt, Germany). TFA (trifluoroacetic acid), TIS
(triisopropylsilane), HEPES (N-(2-hydroxyethyl)piperazine-N-(2-
ethanesulfonic acid)), 2,4,6-collidine and pyrene were purchased
from Sigma-Aldrich (Brøndby, Denmark). Pyridine, sodium
hydroxide pellets and sodium chloride was purchased from J.T.
Baker Chemicals (Phillipsburg, NJ, USA). Filter supports and
Hamilton extrusion syringes, POPG (1-palmitoyl-2-oleoyl-sn-
glycero-3-[phospho-rac-(1-glycerol)] sodium salt), and POPC (1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) were purchased
from Avanti Polar Lipids (Alabaster, AL). All compounds were
used without further purification. Membrane filters for extrusion
(100 nm pore size, polycarbonate) were purchased from Whatman
(Maidstone, UK). Cuvettes (4610 mm, quartz, Suprasil) were
purchased from Hellma (Mu¨llheim, Germany). Purified human
erythrocytes for the haemolysis studies were provided by Bioneer
(Hørsholm, Denmark), and were stored at 4uC for a maximum of
three days before use.
Peptide synthesis and purification
Peptides were prepared by manual Fmoc solid phase peptide
synthesis. Briefly, 3 equivalents of Fmoc-amino acid, 2.98 eq. of
HATU and 6 eq. of 2,4,6-collidine dissolved in DMF were used
for each coupling. Gly required systematic double coupling.
Coupling of each amino acid and Fmoc deprotection was
monitored using the ninhydrin test. Occasionally, a small portion
of resin was cleaved, and the peptide fragment identity was verified
by mass spectrometry to ensure full conversion in the individual
synthetic steps. The peptides were cleaved from the resin using a
mixture of TFA:TIS:H2O (95:2.5:2.5), and the volume of the
cleavage mixture was reduced to ,5% in vacuum or until slight
precipitation occurred. Water was added and the resulting slurry
was subsequently lyophilized. The lyophilized crude peptides were
purified by preparative HPLC and analysed by analytical HPLC
and mass spectrometry.
Preparative HPLC was conducted using a Waters 2489 system
equipped with a Waters Xterra RP18 OBD column, 196150 mm,
Mastoparan-X Analogues
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5 mm particle size. Analytical HPLC was conducted using a
Shimadzu LC-2010C system equipped with a Waters Xterra
RP18 OBD column, 4.66150 mm, 5 mm particle size. The
peptide was detected by UVvis measured at l= 206 nm and
l= 280 nm for both preparative and analytical HPLC. Identity of
the peptide was verified by electrospray ionization mass spec-
trometry (ESI) using an Agilent 1100 LC-MSD with automated
external syringe injection (flow rate 5 ml/min.). The ESI spectra
were obtained in negative mode by scanning in the range from m/
z 300–2000.
Peptide stock solutions
Peptide stock solutions were prepared in a buffer containing
10 mM HEPES and 100 mM sodium chloride (pH = 7.4). All
peptide concentration were determined by UV-VIS (Shimadzu
UV-1700 PharmaSpec) using the molar extinction coefficient of
tryptophan (etryptophan,280 nm = 5600 cm
21 mol21) [28].
LUV preparation
Lipid stock solutions of POPC and POPG were prepared in
chloroform:methanol (9:1). Mixtures of POPC:POPG (3:1) were
prepared and the organic solvent was evaporated under a gentle
stream of nitrogen. The lipid films were kept in vacuum
(P,0.1 Pa) overnight in order to remove the residual solvent.
Buffer containing 10 mM HEPES and 100 mM sodium chloride
(pH 7.4) was added to the lipid films, and they were hydrated for
60 min followed by extrusion through 100 nm using an Avanti
mini-extruder. Dynamic Light Scattering (DLS, Brookhaven
Instrument Corporation, ZetaPALS) was used for measuring the
liposome size distribution. The effective lipid concentration was
determined by inductively coupled plasma atomic emission
spectroscopy (ICP-AES Vista AX, Varian).
Pyrene-cmc assay
Fluorescence excitation spectra were collected using an Olis
modernized SLM8000 fluorescence spectrophotometer equipped
with single-grating emission and double-grating excitation mono-
chromator. The fluorometer was equipped with photon counter
detectors. Pyrene was used to probe micellation as it is sensitive to
environment hydrophobicity. Peptides were incubated in concen-
trations of 0.1–1000 mM in 10 mM HEPES, 100 mM sodium
chloride, pH 7.4 buffer containing 75 nM pyrene. Samples were
incubated for 2 h at 60uC followed by incubation overnight at
room temperature and kept in the dark until measured.
Measurements were carried out at 37uC. Excitation spectra were
collected using emission wavelength 390 nm and 16 nm emission
slit sizes. Excitation spectra were scanned in range 310–350 nm
with excitation slits sizes of 0.5 nm [29]. The excitation spectrum
shift denotes the formation of micelles/aggregates (hydrophobic
cavity), which is gauged by intensity ratio R= I339/I333 [29,30].
The plot of R versus the detergent/peptide concentration, c,
measures the partitioning of pyrene into the formed micelles/
aggregates. The intensity ratio is fitted using the sigmoidal function
R~R0zDR=½1zexp({a(c{ci)), where R0 and DR denote the
initial and change in intensity ratio, respectively. a and ci denote
the normalized slope and peptide concentration at which curve
inflection occurs, respectively. In the present work, cmc is
determined as the onset of the sigmoidal curve, which we have
Figure 1. Structures of MPX and eight analogues. Ala1 and Ala14 have alanine substitution at position 1 or 14, and are analogues with reduced
hydrophobicity. Leu8 has a leucine substitution in position 8 resulting in augmented hydrophobicity. Adec1, Adec8 and Adec14 have 2-amino-
decanoic acid substitution in position 1, 8 or 14 respectively, and constitute the most hydrophobic analogues of MPX considered in this study. PAMPX
and OAMPX are Na-terminal propanoic and octanoic acid acyl analogues of MPX, respectively.
doi:10.1371/journal.pone.0091007.g001
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defined via the criteria (R{R0)=DRw0:1 and hence
cmc~ci{ln(9)=a. The slope of the sigmoidal curve reflects the
cooperativity of the micelle/aggregate formation process and the
partitioning properties of pyrene into the given aggregate. The
experiment was conducted in triplicates.
Peptide partitioning by ITC
The partitioning of AMPs onto lipid membranes was investi-
gated by isothermal titration calorimetry (ITC, iTC200, Microcal,
204 mL cell volume). For the peptide analogues MPX, Ala1 and
Ala14, 10 mM POPC:POPC (3:1) LUVs were injected (1962 mL)
into a 20 mM peptide solution at T = 37uC. The speed of the
stirrer was 1000 rpms, and all titration were initiated with a
0.5 mL pre-injection. The heat-traces were integrated using
custom made software [31], and the heat of partitioning was
analysed using a partitioning isotherm based on Gouy-Chapman-
Stern description of the electrostatic interaction of the peptide and
membrane [14,32]. The effective charge of the peptide (zeff), the
partitioning coefficient of insertion (Kins), the molar enthalpy of
partitioning (DHMw ), and the heat of dilution (qdil) were extracted as
fitting parameters. The effective partitioning coefficient was
derived as Keff~Kins exp({zeff Fqs=RT) where F is Faradays
constant, qs is the electrostatic potential evaluated at the interface
of a fully charged membrane (25mol% negative charge before
insertion of the first peptide), and R is the ideal gas constant. The
instrument was electrically calibrated, and blank titration of LUVs
into buffer was performed to ensure that heat of dilution could be
modelled as a constant in the data analysis. Each titration was
conducted in triplicates.
Mode of peptide-membrane interaction gauged by ITC
The nature of the peptides’ membrane interaction was studied
as a function of lipid/peptide ratio (L/P) by ITC (iTC200,
Microcal). All experiments were conducted by injection of 20 mM
LUVs into 100 mM peptide solution. For OAMPX, 8 mM LUVs
were used. The experiments were conducted as 3861 mL
injections, T = 37uC, and the speed of the stirrer was 1000 rpms.
All titrations were conducted in triplicates.
Haemolysis assay
The assay was conducted as described in Etzerodt et al. [14].
Determination of minimal inhibitory concentration (MIC)
A stock dilution series with ten points, ranging from 1 mM to
1 mM, was prepared in sterile PBS from freshly dissolved peptides.
The dilution series was dispensed in triplicates in 96-deepwell
microtiter plates (VWR Denmark, Herlev, Denmark), with 15 ml
in each well. Multidispensing with electronic pipettes (Biohit,
Ta˚strup, Denmark) was used throughout. Lactococcus lactis, strain
MG1363 (ATCC, LGC Standards AB, Boras, Sweden) and
Escherichia coli, strain INV-a (Invitrogen, Nærum, Denmark) were
grown in M9 (Sigma Aldrich, Brøndby, Denmark) and LB
medium (Difco, BD Biosciences, Brøndby Denmark), respectively.
A single colony was grown overnight at 30uC and 37uC for L.lactis
and E.coli respectively. The next day, a fresh culture was started with
a twenty-fold dilution of the cells and grown for exactly 60 min
(optical density was approximately 0.4 at 570 nm). The cell culture
was diluted (300 fold for L.lactis and 1000 fold for E.coli) before
adding 150 ml to microtiter plates already containing 15 ml peptide
solution and 135 ml fresh medium. Hence, the final concentration
of the peptide dilution series ranged from 0.05 mM to 50 mM.
Plates with L.lactis were sealed with lid and parafilm, and plates
with E.coli were sealed with a gas-permeable tape (VWR
Denmark, Herlev, Denmark). The plates were incubated at the
respective temperatures for 20 hours with shaking (150 rpm). For
each measurement, 100 ml of the cell culture was transferred to
clear, flat-bottomed microtiter plates, and the absorbance at
570 nm was determined using a Victor3 plate reader (Perkin
Elmer, Skovlunde, Denmark). The measurement was conducted in
triplicates.
Results and Discussion
Aggregation
The cmc values for MPX and analogues, which were
investigated using pyrene as a probe for micelle/aggregate
formation (see Fig. 1), are given in Table 1. No shift in the pyrene
excitation spectrum (Fig. 2A) was observed for MPX, Ala1, Ala14
and Leu8 in the covered concentration range, and hence cmc
.1 mM for these analogues. For the C8 modified analogues, cmc
followed the sequence OAMPX.Adec1.Adec8,Adec14. For
simple non-ionic detergents, the cmc is governed by the size of the
hydrophobic tail while the size of the hydrophilic head has smaller
impact [33]. Therefore, if we consider the MPX analogues as
simple detergents, the Adec and OA analogues are expected to
have similar tendency to aggregate with minor variations reflecting
the acylation/alkylation position and charge of the peptide.
Indeed, the Adec1, Adec8, Adec14 and OAMPX analogues are
found to have similar cmc values in correspondence with simple
detergent theory. However, a slight increase in cmc is observed as
the position of the acylchain substitution is moved from the C
towards the N terminal. Based on the Wimley and White
hydrophobicity scale [34], Adec8 is expected to be more
hydrophobic than Adec1, which is predicted to be more
hydrophobic than Adec14. This prediction correlates to the
observed cmc sequence Adec1.Adec8, but not to Adec1.A-
dec14. OAMPX, however, has a lower nominal charge than the
Adec analogues, which in most cases translate to lower cmc values,
contrary to the observed trend. In addition, larger aggregates
visible to the eye were observed for Adec8 at concentrations above
125 mM. These variations in cmc, and the aggregation phenom-
ena of Adec8, may also be explained by differences in flexibility of
the peptide, which possibly adopts different secondary structures
depending on the constraints imposed by the hydrophobic chain.
For Adec8, which is alkylated at the midpoint of the peptide
sequence, the peptide may serve as a bulky headgroup on top of
the C8 acyl chain, which could cause formation of different
structures than the ones formed by the linear molecular constructs
like OAMPX, Adec1 and Adec14. In studies by Tirrell and
coworkers, C14 acylation of the peptide AKK (YGAAKKAA-
KAAKKAAKAA) resulted in a cmc of 130 mM [22]. The Adec1,
Adec8, Adec14 and OAMPX analogues investigated in the
present work thus have equivalent cmc values as the C14 AKK
analogue reflecting the larger hydrophobicity of MPX compared
to AKK.
Membrane partitioning by ITC
For all analogues, partitioning into a POPC:POPG (3:1) lipid
membrane was investigated by ITC. Heat-traces and correspond-
ing heat of reaction are shown in Fig. 3 A–B for the titration of
10 mM POPC:POPG (3:1) 100 nm LUV’s into 20 mM peptide.
PAMPX, Leu8, Adec1, Adec8, Adec14 and OAMPX exhibited
complex heat-traces on ITC, which hampered ITC based analysis
of these analogues. This behaviour is attributed to secondary
processes such as pore formation, lipid segregation or membrane
solubilisation/micellation. The ITC results for or MPX, Ala1 and
Ala14, which are summarized in Table 1, are interpreted using a
Mastoparan-X Analogues
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partitioning isotherm based on the Gouy-Chapman-Stern model
[14,32]. Here K0 quantifies the interaction of the analogue with a
neutral/zwitterionic membrane; Keff, measures interaction of the
analogue with a negatively charged membrane, and the effective
charge, zeff, governs the electrostatic interactions of the lipid
membrane and the peptide. The partitioning process is exothermic
for Ala1, Ala14, and MPX, and the molar enthalpy of partitioning
(DHMw ) increases upon alanine substitution for both Ala1 and
Ala14. For MPX, the partitioning coefficients determined by ITC
(Table 1) agree with our previous result (Kins~3:7:10
5 and
Keff~2:3:10
7), which was obtained via tryptophan fluorescence
measurements [14]. However, the effective charge obtained by
ITC (Table 1), is slightly larger than our previous result of 1.7 [14],
which accounts for the increase in Keff in our current measurement.
Schwartz and co-workers found a partitioning coefficient of
insertion (MPX into POPC LUVs), Kins~2:2:10
5 [35], which is in
accordance with our result.
Overall, Ala1 and Ala14 show reduced Kins and increased zeff
and DHMw as a result of alanine substitution. The observed inverse
correlation of zeff and Kins is in accordance with previous findings
by White and co-workers, who showed that the effective charge is
inversely proportional to the free energy of inserting a peptide into
a lipid membrane [36]. The alanine substituted analogues, Ala1
and Ala14, are less hydrophobic compared to MPX, which
translates to a reduction in the partitioning coefficient of insertion
as expected. For Ala1, the reduction in Kins is compensated by an
augmented effective charge (compared to MPX), which leads to an
overall increase of the effective partitioning coefficient (Keff) when
compared to MPX. For Ala14, the increase in effective charge
does not balance the decrease in Kins yielding an overall reduction
of Keff. In order to evaluate the performance of the peptide
analogues, the membrane charge selectivity (ability to distinguish
charged and neutral lipid membranes) is assessed via the ratio
Keff =Kins~exp({zeff Fqs=RT) (Fig. 3C). The relative change in
potency (propensity for insertion/partitioning) compared to MPX
is evaluated via the ratio Keff/Keff(MPX) or Kins/Kins(MPX) for
anionic and neutral lipid membranes, respectively (Fig. 3C). Based
on this analysis, Ala1 shows increased charge selectivity, increased
potency towards anionic lipid membranes, and reduced potency
towards neutral lipid membranes when compared to MPX
(Fig. 3C). Ala14 displays a minor increase in charge selectivity,
but a reduction in potency towards both anionic and neutral lipid
Figure 2. Critical micelle concentration assessed via fluores-
cence spectroscopy. As an example, pyrene fluorescence excitation
spectra are shown for a concentration sequence of Adec8 in (A). The
formation of micelles is monitored via partitioning of pyrene into the
hydrophobic cavity of the forming micelles. This induces the observed
peak-shift of pyrene (A), which is quantified via the intensity ratio
R = I339/I333 plotted in (B) as a function of peptide concentration. In the
current work, the cmc is defined as the point where R deviates from the
background signal.
doi:10.1371/journal.pone.0091007.g002
Table 1. Compilation of results.
cmc zeff Kins/10
5 Keff/10
8 DHMw MIC (L. lactis) MIC (E. coli) H5
MPX .1000 2.560.1 4.260.2 1.660.2 224.060.3 2.560.5 863 1862
Ala1 .1000 4.360.1 1.160.1 2567 218.460.3 1867 3368 230610
Ala14 .1000 2.960.1 1.460.3 1.160.2 216.260.3 2164 3368 220620
PAMPX .1000 ----------- ----------- ----------- ----------- 3.360.8 2164 2561
Leu8 .1000 ----------- ----------- ----------- ----------- 2.561.3 763 1462
Adec1 90610 ----------- ----------- ----------- ----------- 1.760.4 3.360.8 0.760.1
Adec8 3067 ----------- ----------- ----------- ----------- 4.260.8 4.260.8 161
Adec14 10620 ----------- ----------- ----------- ----------- 1.760.4 3.360.8 0.860.2
OAMPX 150650 ----------- ----------- ----------- ----------- 3.360.8 561 1.160.3
Critical micelle concentration (cmc in mM units), effective charge (zeff) of the peptide, partition coefficient of insertion (Kins), effective partition coefficient (Keff), molar
enthalpy of partitioning (DHMw in kJ/mol units), minimal inhibitory concentration (MIC in mM units) and the haemolytic potency is given as the concentration H5 (in mM
units) at which 5% haemolysis has been obtained. Membrane partitioning data for PAMPX, Leu8, Adec1, Adec8, Adec14 and OAMPX could not be analysed and these
cells are marked with a dashed line.
doi:10.1371/journal.pone.0091007.t001
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membranes compared to MPX (Fig. 3C). Based on the ITC
results, we predict Ala1 to be more selective, more potent towards
bacteria, and less haemolytic than MPX. Ala14 however, is
expected to be less potent and haemolytic, but slightly more
selective than MPX. The observed increase in the Keff/Kins ratio for
the Ala analogues (reduced hydrophobicity compared to MPX) is
also in line with our previous finding for OAMPX. In that study,
we found that Keff/Kins was reduced in response to an increased
hydrophobicity [14].
Mode of peptide-membrane interaction gauged by ITC
The mode of peptide-membrane interaction was investigated by
ITC. This study was conducted using a modified titration protocol
having an increased peptide concentration (in the ITC cell)
compared to the partitioning studies. The higher peptide to lipid
ratio utilized in this assay facilitates the occurrence of multiple
events including: dilution, membrane partitioning, pore formation,
lipid segregation and micellation/solubilisation of the membrane
[10]. Each process contributes to the heat-trace and heat of
reaction (Fig. 4A–F) with a unique signature. The three latter
processes, which are referred to as secondary or reversible
processes in this work, are ideally reversible as demonstrated for
pore formation in a recent work [10,37]. For such reversible
events, the direction of the process, e.g. pore-formation, lipid
segregation or micellation, may revert during the titration
sequence. This typically shows as, exothermic heat spikes followed
by endothermic heat spikes due to initial formation and
subsequent disintegration of a membrane structure e.g. pores. In
this study, ITC was used as a screening tool to clarify whether: (i)
the peptide analogues interact with POPC:POPG (3:1) LUVs via
peripheral insertion (partitioning) or (ii) if secondary/reversible
processes occur as for the native MPX peptide. In Fig. 4A–C,
signatures for secondary/reversible processes are observed for
MPX, Leu8, Adec1, Adec14, PAMPX and OAMPX but not for
Ala1 and Ala14. For MPX, Leu8, Adec1, Adec14, PAMPX and
OAMPX, the signatures are similar to ITC heat-traces previously
observed for the pore formation of magainin2, PGLa and MPX
[10,16,38]. The heat-traces for both Ala analogues (Fig. 4A) are
monotonic and resemble the heat-trace for membrane partitioning
(as shown in Fig. 3A). The changed behaviour of Ala1 and Ala14
can possibly be explained by the reduced affinity for POPC:POPG
(3:1) lipid membranes (confirmed by partitioning studies), which
decrease the membrane surface density of the Ala analogue and
thereby the membrane aggregate formation propensity. However,
Leu8, Adec1, Adec14, PAMPX and OAMPX have preserved the
MPX ITC signature and may form pores, peptide aggregates or
solubilize the POPC:POPG (3:1) membrane at these conditions.
The endpoint of the reversible process (highlighted using black
arrows in Fig. 4D–F) displays the endpoint sequence
MPX,PAMPX,Adec1,Adec14 (L/P,21).Leu8 (L/
P,16).OAMPX (L/P,11). A large L/P endpoint implies a
strongly favoured secondary process as it is difficult to supress by
dilution (increasing the L/P ratio). Hence, MPX, PAMPX, Adec1
and Adec14 are more prone to form pores, peptide clusters etc.,
whereas Leu8 and OAMPX require larger peptide surface
densities for these processes to occur. The L/P endpoint obtained
for MPX at 37uC is in accordance with our previous finding for
MPX at 25uC [10]. For Adec8, the titration was compromised by
formation of large aggregates (visual by eye) after the 4’th injection
which resulted in a noisy heat-trace. The larger propensity of
Adec8 to solubilize the membrane may be related the non-linear
molecular structure of this analogue as discussed earlier.
Bactericidal and haemolytic studies
Bactericidal and haemolytic studies were conducted, and the
results are summarized in Fig. 5 and Table 1. The results are
reported as the minimal inhibitory concentrations (MICs) and
%haemolysis of human red blood cells (RBCs), which is given as a
function of peptide concentration. Adec1, Adec8, Adec14 and
OAMPX show the largest potency towards RBCs followed by
MPX and Leu8, the latter being slight more potent than MPX at
the highest concentrations. PAMPX is found to be less haemolytic
than MPX as shown previously [14], while the haemolytic effect of
Ala1 and Ala14 is almost completely abolished (,4% haemolysis
Figure 3. Partitioning of MPX, Ala1 and Ala14 onto POPC:POPG
(3:1) LUVs studied via ITC at 376C. In panel (A), heat traces of
25 mM LUVs injected into 20 mM peptide (1962 mL injections) are
shown. Panel (B) shows the corresponding heat of reaction, Q, as a
function of number of injections. The solid lines in (B) represent fits to
the data. In panel C, the change in potency of Ala1 and Ala14 for neutral
or anionic lipid membranes measured relative to MPX, is evaluated via
the ratio Kins/Kins(MPX) and Keff/Keff(MPX) respectively. The membrane
charge selectivity of the peptide (ability to select between neutral and
anionic lipid membranes) is assessed via the partitioning coefficient
ratio Keff/Kins shown in (C).
doi:10.1371/journal.pone.0091007.g003
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at 200 mM). To illustrate this point, full haemolysis is obtained at
50 mM peptide for OAMPX, Adec1, Adec8 and Adec14, while
only 15% haemolysis is found for MPX, 10% for PAMPX and
,1.5% for Ala1 and Ala14. The observed increase in haemolysis
for the C8 modified analogues (Adec1, Adec8, Adec14, OAMPX)
is in accordance with several reports of C8–C16 acylated peptides,
which display increased haemolytic activity upon acylation
[24,26,39].
The bactericidal potency of Adec1, Adec8, Adec14, OAMPX
and Leu8 to L. lactis is similar to the potency of MPX, while
Adec1, Adec8, Adec14 and OAMPX are ,2 fold more potent
towards E. coli than native MPX. Contrary, Ala1 and Ala14 show
an 8 fold and 4 fold reduction, respectively, in their potency
towards L. lactis and E. coli, compared to MPX. PAMPX was
found to be equally potent towards L. lactis as MPX, but 3 fold less
potent towards E. coli.
In order to evaluate the benefit of the substitution for the eight
analogues, their selectivity towards bacteria and RBCs were
compared, which is presented as the ratio H5/MIC in Fig. 6. H5
denotes the concentration at which 5% haemolysis has been
obtained. As a rule of thumb, H5/MIC..1 indicate a treatment
regime where haemolysis can be avoided at a potent administered
Figure 4. Mode of peptide-membrane interaction evaluated using ITC at 376C. Panel A–C shows the heat trace of 20 mM POPC:POPG (3:1)
LUVs injected into 100 mM peptide (3861 mL injections), except for OAMPX which was titrated using 8 mM LUVs. The corresponding heat of reaction
(Q) and accumulated heat of reaction (Qacc) are shown in panel D–F and G–I respectively. The arrows in panel D–F highlight the endpoint of the
secondary process and the solid lines serve to guide the eye.
doi:10.1371/journal.pone.0091007.g004
Figure 5. Bactericidal potency of MPX and analogues. The
degree of red blood cell haemolysis is plotted as a function of peptide
concentration.
doi:10.1371/journal.pone.0091007.g005
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dose (peptide concentration.MIC) while H5/MIC,1 implies the
opposite; a regime where the peptide targets both bacteria and
RBCs. This analysis shows that MPX has a wider treatment
window for L. lactis compared to E. coli. Moreover, Ala1 and Ala14
display an increased H5/MIC value for both L. lactis and E. coli
compared to MPX, while PAMPX and Leu8 show similar
selectivity as MPX towards both bacteria strains. Adec1, Adec8,
Adec14 and OAMPX show an approximate 15 fold reduction in
H5/MIC value compared to MPX, which render these analogues
more potent towards RBCs than the tested bacteria strains.
Although PAMPX did not show an increased selectivity, as
expected from previous work [14], the abolished selectivity of
OAMPX correlates with the highly reduced effective charge found
previously [14]. The observed reduction in selectivity upon
acylation, is furthermore supported by examples in literature [24].
In a recent work, we investigated the secondary structure of
MPX, PAMPX and OAMPX using CD (14). In buffer, the
analogues predominantly formed beta-sheets and turns (55%), and
in the presence of lipid membranes, the analogues were largely
structured in alpha-helical segments (50–65%). Overall, MPX,
PAMPX and OAMPX exhibited similar behavior respect to
structure, and no direct correlation to recent or present results can
be established.
The investigated analogues can be divided into 3 groups
according to their hydrophobicity: C1 analogues (Ala1 and Ala14)
with reduced hydrophobicity, C3-4 analogues (PAMPX and Leu8)
with a slightly increased hydrophobicity and C8 analogues (Adec1,
Adec8, Adec14 and OAMPX) having the largest increase in
hydrophobicity compared to MPX.
The C1 group did not aggregate below 1 mM, and partitions to
less readily into neutral lipid membranes (see Kins, Table 1)
compared to MPX. These observations correlate to the almost
abolished haemolytic property observed in the RBC assay
(Fig. 5A). The C1 analogues showed larger membrane selectivity
as measured by the model membrane based Keff/Kins index
(Fig. 2C). Similar increase in selectivity was observed for the
bactericidal- and haemolytic-based H5/MIC index for both of the
tested bacterial strains (Fig. 6). For Ala1, Keff was increased
corresponding to enhanced interaction with negatively charged
membranes; however, this observation did not translate into an
increased bacterial potency for any of the tested bacterial strains
(Table 1). Judged by membrane selectivity (Keff/Kins), membrane
partitioning (Keff), and gain in effective charge (zeff), Ala1 is superior
to Ala14, which correlates to the trend (although not significant)
observed for the H5/MIC index (Fig. 6). Furthermore, ITC heat-
traces point to the conclusion, that the mode of membrane
interaction is altered as a result of the weaker membrane affinity
for both Ala analogues. Alanine substitution (reduction in
hydrophobicity) at position 1 compared to position 14 results in
a larger increase in effective charge and hence selectivity. This
observation may be rationalized by the close proximity of the N-
terminal charge in position 1 compared to the larger distance to
the neighbouring lysine at position 14 (See Fig. 1).
The C3-4 group did not display aggregation below 1 mM, and
the mode of membrane interaction was unaltered as gauged by
ITC. Leu8 showed similar bactericidal properties as MPX for both
L. lactis and E. coli. PAMPX exhibited 3-fold lower activity towards
E. coli, but equivalent activity as MPX towards L. lactis. The C3-4
analogues showed similar potency towards RBCs as MPX, where
Leu8 is slightly more potent and PAMPX slightly less potent than
MPX. The latter finding is in correspondence with previous
observation for PAMPX [14]. Augmented hydrophobicity in
position 1 or 8 (see Fig. 1) thus does not impair or boost potency
towards bacteria or RBCs, which renders the therapeutic window
unaffected.
All C8 class analogues aggregated in the concentration range
10–150 mM, and the cmc’s follow the sequence: OAMPX.Ade-
c1.Adec8,Adec14. Traditional non-ionic surfactants with C8
carbon chain as the hydrophobic moiety have cmc values in the
10 mM range [33]. This is 100–1000 fold higher than cmc of the
present analogues, which indicate that the peptide contributes
significantly to the overall hydrophobicity of the acylated
analogue, and hence to the further reduction of cmc. For all C8
class analogues, the cmc was significantly larger than their MIC
and concentration at which full RBC lysis was obtained. Hence,
peptide aggregation does not contribute significantly to the
biological function of the C8 analogues. Adec1, Adec14 and
OAMPX exhibited similar heat-trace profile as MPX (Fig. 4),
which indicates unchanged mode of membrane interaction.
Adec8, however, showed tendency to aggregate in solution above
125 mM, which caused formation of large aggregates in the ITC
experiment when injecting 10 mM LUVs into 100 mM Adec8
solution. All C8 analogues displayed equivalent or slightly
increased bactericidal potency compared to MPX; however, their
selectivity was significantly reduced causing a radical narrowing of
the therapeutic window (Fig. 6).
Conclusion
Six novel and two known analogues of MPX, having modulated
hydrophobicity at position 1, 8 and 14, were investigated using a
combined biophysical and biological approach. ITC, bactericidal
and haemolytic studies revealed an improved membrane selectiv-
ity for alanine substitution at position 1 or 14 of MPX. Leucine
substitution at position 8, however, rendered the biological
function unaltered. Effects related to the proximity of hydrophobic
and charged groups were investigated. This showed that reduction
in hydrophobicity close to the N-terminal leads to a larger gain in
effective charge and membrane selectivity compared to a
reduction of hydrophobicity at position 14; a position more distal
to the next lysine. Substitution by 2-amino-decanoic acid at
position 1, 8 or 14 or acylation using octanoic acid of MPX
rendered these analogues equally or slightly more potent than
MPX, however, the membrane selectivity was significantly
impaired. Overall these results show that both membrane
selectivity and peptide potency can be optimized by acylation/
Figure 6. Therapeutic window (membrane selectivity) of MPX
and analogues evaluated via the ratio H5/MIC. H5 is the peptide
concentration at which 5% haemolysis has occurred and MIC is minimal
inhibitory concentration.
doi:10.1371/journal.pone.0091007.g006
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alkylation; still, the present study show that potency is gained at
the expense of impaired membrane selectivity or vice versa.
Increasing hydrophobicity might improve selectivity in some cases,
while in others the selectivity is abolished changing the lipo-
peptides’ mode of action to a simple detergent-like mechanism that
does not distinguish between bacterial and mammalian mem-
branes. The desire for higher potency or membrane selectivity
thus determines whether a strategy of increased (alkylation or
acylation) or reduced hydrophobicity (alanine or glycine substitu-
tion) should be pursued.
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